Twelve-week treatment with BOS-580, a novel, long-acting Fc-FGF-21 fusion protein, leads to a reduction in liver steatosis, liver injury, and fibrosis in patients with phenotypic NASH: a randomized, blinded, placebo-controlled phase 2A trial

Rohit Loomba,Kris Kowdley,Jose Rodriguez,Nomita Kim, Alina Alvarez,Linda Morrow, Philip Yin,Lakshmi Amaravadi, Brenda Jeglinski, Alicia Clawson, Swapan Chowdhury,Craig Basson, Etienne Dumont, Eric Svensson, Tatjana Odrljin

Journal of Hepatology（2023）

引用 0|浏览7

暂无评分

关键词

liver steatosis,fibrosis,liver injury,twelve-week,long-acting,fc-fgf,placebo-controlled

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要